Ranbaxy Alleges Rivals Of Meddling With Daiichi Sankyo Deal; U.S. House Committee Enters Fray
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's leading drug maker Ranbaxy Laboratories has alleged that global big pharma players are trying to scuttle its acquisition by Daiichi Sankyo. U.S. FDA and the U.S. Department of Justice's probe of Ranbaxy is part of a larger battle against the company, CEO Malvinder Singh said in a television interview on Friday, indicating that vested interests in the global industry were trying to stall the deal
You may also be interested in...
Ranbaxy CEO Malvinder Singh On U.S. FDA’s Investigation And The Daiichi Sankyo Deal: An Interview With PharmAsia News
During the last few months, India's largest drug maker Ranbaxy has been in the news more than almost any other manufacturer. Ranbaxy settled patent disputes on two of the largest global drug brands, Lipitor and Nexium. The company's CEO Malvinder Singh sealed a "game-changer" deal with Japan's third largest drug maker Daiichi Sankyo and sold 34.8 percent of his personal and family stake for over $4 billion (PharmAsia News, June 11, 2008). And a U.S FDA investigation of Ranbaxy continues to heat up over allegations of good manufacturing practices deviations at one of the company's manufacturing sites in India (PharmAsia News, July 29, 2008). This week, PharmAsia News' India bureau sat down with Singh to get his take on the action.
Ranbaxy CEO Malvinder Singh On U.S. FDA’s Investigation And The Daiichi Sankyo Deal: An Interview With PharmAsia News
During the last few months, India's largest drug maker Ranbaxy has been in the news more than almost any other manufacturer. Ranbaxy settled patent disputes on two of the largest global drug brands, Lipitor and Nexium. The company's CEO Malvinder Singh sealed a "game-changer" deal with Japan's third largest drug maker Daiichi Sankyo and sold 34.8 percent of his personal and family stake for over $4 billion (PharmAsia News, June 11, 2008). And a U.S FDA investigation of Ranbaxy continues to heat up over allegations of good manufacturing practices deviations at one of the company's manufacturing sites in India (PharmAsia News, July 29, 2008). This week, PharmAsia News' India bureau sat down with Singh to get his take on the action.
Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel - CEO Interview
MUMBAI - India's largest drug maker Ranbaxy is confident that the U.S. Department of Justice will soon withdraw its motion filed against the company, Ranbaxy CEO Malvinder Singh said in an interview with PharmAsia News